BST — Biotechnology Assets SA Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual cashflow statement for Biotechnology Assets SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	C2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Depreciation
Amortisation
Non-Cash Items	-7.01	-7.01	0.58	0.074	0.158
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-10.2	13.6	-4.11	-2.24	-2.58
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-15.2	8.79	-1.5	-0.017	0.048
Capital Expenditures	-7.48	-0.392	-0.661	-2.12	-0.326
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	—	45.2	0	0	—
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-7.48	44.8	-0.661	-2.12	-0.326
Financing Cash Flow Items	0.986	0.085	—	-0.06	-0.37
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	23.5	-57.8	3.28	1.15	-0.061
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	0.818	-4.21	1.12	-0.985	-0.339